Lyudmila V. Verkhovskaya

Lyudmila V. Verkhovskaya

Auto-generated profile, based on publicly available information

Lyudmila V. Verkhovskaya

National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya, Ministry of Health of the Russian Federation, Moscow

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AKAlexey Kostarnoy
Alexey Kostarnoy
PGPetya G. Gancheva
Petya G. Gancheva
BLBernd Lepenies
Bernd Lepenies
Amir I. TukhvatulinAmir I. Tukhvatulin
Amir I. Tukhvatulin
ADAlina S. Dzharullaeva
Alina S. Dzharullaeva
AGAlexander L. Gintsburg
Alexander L. Gintsburg
Significance: Post-traumatic sterile inflammation is the first necessary step of wound healing. In addition, sterile inflammation underlies the pathogenesis of a multitude of common diseases, such as allergies and autoimmune diseases. The molecular mechanisms underlying sterile inflammation are still not fully understood. Here, we show that the receptor Mincle (Clec4e), the expression of which is highly induced in the skin in response to damage, recognizes cholesterol sulfate, a molecule that is abundant in the epidermal layer of the skin, subsequently inducing a pro-inflammatory response. We also identify a role for Mincle as a driving component in the pathogenesis of allergic skin inflammation. The results demonstrate a previously unconsidered important role of Mincle in mediating sterile inflammation.

20 March 2023 in Fine Chemical Technologies
Verified
Journal Article
Open access
PDF file
ESE. S. Sedova
E. S. Sedova
DSD.N. Shcherbinin
D.N. Shcherbinin
BABandelyuk Alina
Bandelyuk Alina
LVL. V. Verkhovskaya
L. V. Verkhovskaya
NVN. Yu. Viskova
N. Yu. Viskova
MSMaxim Shmarov
Maxim Shmarov
Objectives. To develop a technology for obtaining recombinant antibodies in a suspension culture of human HEK293 cells using transduction with recombinant adenovirus serotype 5 (rAd5) carrying genes expressing heavy and light chains of antibodies on the example of two broadspectrum anti-influenza antibodies 27F3 and CR9114.Methods. Ad5-27F3-H, Ad5-CR9114-H, and Ad5-27F3-L recombinant adenoviruses carrying the 27F3 antibody heavy chain gene, CR9114 antibody heavy chain gene, and 27F3 light chain gene, respectively, were generated using the AdEasy™ Adenoviral vector system. To accumulate preparative amounts of recombinant r27F3 and rCR9114 antibodies, the HEK293 suspension cell line was transduced with recombinant adenoviruses carrying genes for heavy and light chains of antibodies. The cells were cultured in a wave-type bioreactor. Chromatography was used to purify recombinant antibodies from the culture medium. After analyzing the molecular weights of purified antibodies using protein electrophoresis, their ability to interact with influenza A and B viruses was analyzed using the Western blot technique, while their ability to neutralize influenza A and B viruses was evaluated using the virus neutralization assay.Results. A method for the accumulation and purification of recombinant r27F3 and CR9114 antibodies from the culture medium of a suspension culture of human cells following transduction with its recombinant adenoviruses carrying the genes for heavy and light chains of these antibodies was developed. The ability of the r27F3 antibody to interact with and neutralize influenza A viruses of group 1 (except influenza A virus subtype H2) and group 2 was shown. The ability of the rCR9114 antibody to interact with influenza A viruses of group 1 and influenza B viruses, as well as to neutralize influenza A viruses of group 1, was demonstrated.Conclusions. A technology for obtaining recombinant antibodies in a suspension culture of HEK293 cells using transduction with recombinant adenoviruses carrying genes expressing heavy and light chains of antibodies was developed along with a confirmation of their specificity.

16 July 2025 in Fine Chemical Technologies
Verified
Journal Article
Open access
PDF file
EAElena Avdonina
Elena Avdonina
KPK. A. Pervoykina
K. A. Pervoykina
LVL. V. Verkhovskaya
L. V. Verkhovskaya
DSD.N. Shcherbinin
D.N. Shcherbinin
NVN. Yu. Viskova
N. Yu. Viskova
ITI. N. Tyurin
I. N. Tyurin
Production of the recombinant hemagglutinin protein of the swine influenza virus A/H1N1 and analysis of its physicochemical and antigenic properties

21 March 2025 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
MSMaxim Shmarov
Maxim Shmarov
SAS. V. Alekseeva
S. V. Alekseeva
NDN. A. Dovzhenko
N. A. Dovzhenko
BABandelyuk Alina
Bandelyuk Alina
IEIlias B Esmagambetov
Ilias B Esmagambetov
AGA. L. Gintsburg
A. L. Gintsburg
INTRODUCTION. The development of universal influenza vaccines based on conserved influenza virus antigens is a promising strategy for preventing pandemic influenza. Recombinant vaccines based on adenoviral vectors have high antiviral potential and have proven their effectiveness during the COVID-19 pandemic. In this regard, the development and clinical evaluation of a viral vector vaccine against influenza A seem relevant.AIM. The aim was to evaluate the safety, reactogenicity, and immunogenicity of a broad-spectrum viral vector vaccine against influenza A after a single intranasal administration in healthy volunteers.MATERIALS AND METHODS. This clinical trial studied the GamFluVac recombinant human adenovirus serotype 5 (rAd5)-based vaccine against influenza A (National Research Center for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya). The clinical trial enrolled 36 volunteers. The follow-up period was 28 days. The safety assessment of the viral vector vaccine was based on the incidence, nature, and severity of adverse events (AEs) after a single intranasal administration at doses of 2.5×1010 (Group 1), 1.0×1011 (Group 2), and 2.5×1011 (Group 3) viral particles. Immunogenicity was evaluated by measuring serum IgG antibodies against influenza A (H5N2) by enzyme immunoassay on Day 0 and Day 28.RESULTS. No serious or severe AEs were reported during the clinical trial. Most AEs associated with the vaccine manifested as respiratory disorders, abnormal blood findings, and general disorders (elevated body temperature, headache, chills, malaise, arthralgia, and myalgia). Statistically significant differences (p=0.0285) were identified in the incidence of general disorders and administration site conditions in Group 1 (0%), Group 2 (16.7%), and Group 3 (33.3%). Group 3 demonstrated the highest increase in the geometric mean titres of specific IgG antibodies (2.8 times the baseline) on Day 28. In this group, 100% of volunteers had a ≥2-fold seroconversion rate, and 41.7% of volunteers had a ≥4-fold seroconversion rate.CONCLUSIONS. This phase I clinical trial of the GamFluVac viral vector vaccine against influenza A demonstrated the immunogenicity and favourable safety profile of the vaccine after a single intranasal administration.

1 January 2020 in Immunologiya
Verified
Journal Article
Open access
FFFederal Research Centre for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation
Federal Research Centre for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation
MSMaxim Shmarov
Maxim Shmarov
IUI.M. Sechenov First Moscow State Medical University of Ministry of Health of the Russian Federation (Sechenov University)
I.M. Sechenov First Moscow State Medical University of Ministry of Health of the Russian Federation (Sechenov University)
ESE.S. Sedova
E.S. Sedova
ANA.E. Nikonova
A.E. Nikonova
AGA.L. Gintsburg
A.L. Gintsburg

1 January 2024 in Immunologiya
Verified
Journal Article
Open access
KPK.A. Pervoykina
K.A. Pervoykina
DSD.N. Shcherbinin
D.N. Shcherbinin
VVV.M. Vakhtinskii
V.M. Vakhtinskii
EAElena Avdonina
Elena Avdonina
LVL.V. Verkhovskaya
L.V. Verkhovskaya
AGA.L. Gintsburg
A.L. Gintsburg
Иммуногенность протективного антигена Bacillus anthracis в составе иммуномодулирующих конструкций